Aganirsen drops inhibit neovascularization

Article

Aganirsen eye drops inhibited corneal neovascularization in patients with keratitis and reduced the need for transplantation in patients who have viral keratitis and central neovascularization, according to a Phase III study of 69 patients.

Aganirsen eye drops inhibited corneal neovascularization in patients with keratitis and reduced the need for transplantation in patients who have viral keratitis and central neovascularization, according to a Phase III study of 69 patients reported in Ophthalmology. Aganirsen is an antisense oligonucleotide preventing insulin receptor substrate-1 expression.

Researchers in the I-CAN Study randomized 34 patients with keratitis-related progressive corneal neovascularization to receive aganirsen (86 μg/day/eye) and 35 patients to receive placebo. The patients administered the drops twice daily for 90 days and were followed up to day 180.

After 90 days, the patients in the aganirsen group had a 26% reduction in the relative corneal neovascularization area (P = 0.014). This improvement was maintained after 180 days (P = 0.012). The patients in the aganirsen group had a lower transplantation need in the intent-to-treat population at day 180 (P = 0.087). In addition, a significant reduction in transplantation need was achieved in patients with viral keratitis and central neovascularization (P = 0.048).

No significant differences in visual acuity scores or graft rejection were observed between the two groups, but patients in the aganirsen group with traumatic/viral keratitis tended to have a reduced risk of graft rejection at day 90 (P = 0.162).

A quality-of-life analysis found a significant improvement in composite and near activity subscores in the aganirsen group at day 90.

To read an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.